Omnicell, Inc., provides medication management automation solutions and adherence tools for health care systems and pharmacies in the United States and internationally. The company is headquartered in Mountain View, California.
| Revenue (TTM) | $1.23B |
| Gross Profit (TTM) | $537.47M |
| EBITDA | $73.61M |
| Operating Margin | 5.44% |
| Return on Equity | 1.63% |
| Return on Assets | 1.21% |
| Revenue/Share (TTM) | $26.84 |
| Book Value | $27.63 |
| Price-to-Book | 1.64 |
| Price-to-Sales (TTM) | 1.63 |
| EV/Revenue | 1.637 |
| EV/EBITDA | 16.87 |
| Quarterly Earnings Growth (YoY) | -35.90% |
| Quarterly Revenue Growth (YoY) | 14.90% |
| Shares Outstanding | $45.48M |
| Float | $41.94M |
| % Insiders | 2.22% |
| % Institutions | 105.88% |
Volatility is currently contracting
Shares of Omnicell OMCL have rallied 52.6% over the past year, significantly outperforming the industry's 20.8% fall and the S&P 500 composite's 23.9% gain.
FORT WORTH, Texas--(BUSINESS WIRE)--Nnamdi Njoku appointed President of Omnicell leading global operations & innovation strategy; Randall Lipps continues as CEO, Chairman of the Board.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
Investors need to pay close attention to OMCL stock based on the movements in the options market lately.
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks is more attractive to value investors?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Omnicell, Inc. (OMCL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Omnicell is rated Buy, with Q1 results showing structural margin improvement and a 660 bps operating margin jump. Q1 revenue grew 15% Y/Y to $310M, with non-GAAP EPS of $0.55 beating guidance by 53% and free cash flow tripling to $39M. Management raised FY 2026 EBITDA guidance, expects margin expansion to outpace revenue growth, and continues share repurchases.
Robotics stocks like ABB gain traction as 2026 marks a surge in AI-driven automation, new cobots and strategic deals shaping the sector's next growth wave.
